30165
Tirofiban
≥98.5% (HPLC)
동의어(들):
(2S)-2-(Butylsulfonylamino)-3-{4-[4-(4-piperidyl)butoxy}phenyl propanoic acid, N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C22H36N2O5S
CAS Number:
Molecular Weight:
440.60
Beilstein:
6182267
MDL number:
UNSPSC 코드:
12352106
PubChem Substance ID:
NACRES:
NA.25
추천 제품
Quality Level
분석
≥98.5% (HPLC)
형태
powder
SMILES string
CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O
InChI
1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1
InChI key
COKMIXFXJJXBQG-NRFANRHFSA-N
유전자 정보
human ... ITGA2B(3674) , ITGB3(3690)
애플리케이션
- The efficacy and safety of continuous intravenous tirofiban for acute ischemic stroke patients treated by endovascular therapy: a meta-analysis.: This meta-analysis assesses the safety and efficacy of continuous intravenous tirofiban in patients undergoing endovascular therapy for acute ischemic stroke, showing promising results for improved outcomes (Wang et al., 2024).
- Initial Experience with a New Self-Expanding Open-Cell Stent System with Antithrombotic Hydrophilic Polymer Coating (pEGASUS Stent) in the Treatment of Wide-Necked Intracranial Aneurysms.: This study reports on the initial use of a new stent system coated with tirofiban in treating intracranial aneurysms, demonstrating enhanced safety and efficacy (Boxberg et al., 2024).
포장
Bottomless glass bottle. Contents are inside inserted fused cone.
신호어
Warning
유해 및 위험 성명서
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
표적 기관
Respiratory system
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
개인 보호 장비
dust mask type N95 (US), Eyeshields, Gloves
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
Marco Valgimigli et al.
European heart journal, 31(1), 35-49 (2009-09-17)
To perform a thorough and updated systematic review of randomized clinical trials comparing tirofiban vs. placebo or vs. abciximab. We searched for randomized trials comparing tirofiban vs. placebo or any active control. Odds ratios (OR) were computed from individual studies
Marco Valgimigli et al.
JACC. Cardiovascular interventions, 5(3), 268-277 (2012-03-24)
The authors sought to compare the effect on inhibition of platelet aggregation (IPA) of prasugrel therapy versus tirofiban bolus with or without a post-bolus short drug infusion in ST-segment elevation myocardial infarction (STEMI) patients. The degree and rapidity of IPA
Nohra Chalouhi et al.
Neurosurgery, 71(3), 710-714 (2012-06-07)
Thromboembolic complications are a major concern in stent-assisted coiling of intracranial aneurysms that may be prevented with adequate antiplatelet therapy. To assess the safety and efficacy of tirofiban in stent-assisted coiling. Two protocols were used. In the initial protocol, tirofiban
Shukri W David et al.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 93(5), 882-890 (2018-09-29)
In the randomized AMIHOT-II trial, supersaturated oxygen [SSO2 ] delivered into the left anterior descending (LAD) artery via an indwelling intracoronary infusion catheter following primary percutaneous coronary intervention (PCI) significantly reduced infarct size in patients with anterior ST-segment elevation myocardial
Christoph Kabbasch et al.
Journal of neurointerventional surgery, 11(8), 812-816 (2019-01-25)
Intrasaccular flow disruption represents a new paradigm in endovascular treatment of wide-necked bifurcation aneurysms. To perform a matched case-control study comparing complications and angiographic outcome using the Woven Endobridge (WEB) device and stent-assisted coiling (SAC). Sixty-six patients treated with the
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.